Samuel Wadsworth
Director Técnico/Científico/I+D en ULTRAGENYX PHARMACEUTICAL INC. .
Fortuna: 54 206 $ al 31/05/2024
Perfil
Samuel C.
Wadsworth is an Independent Director at Precision BioSciences, Inc. since 2021 and the Chief Scientific Officer at Ultragenyx Pharmaceutical, Inc. since 2017.
Previously, he worked as the Director-Molecular Biology at Genzyme Corp.
from 2010 to 2013 and as the Chief Scientific Officer at Dimension Therapeutics, Inc. from 2013 to 2017.
Dr. Wadsworth holds a doctorate degree from The University of Chicago and an undergraduate degree from Southern Illinois University.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 04/06/2024 | 4 202 ( 0.06% ) | 54 206 $ | 31/05/2024 |
Cargos activos de Samuel Wadsworth
| Empresas | Cargo | Inicio |
|---|---|---|
| ULTRAGENYX PHARMACEUTICAL INC. | Director Técnico/Científico/I+D | 01/11/2017 |
| PRECISION BIOSCIENCES, INC. | Director/Miembro de la Junta | 06/11/2021 |
Antiguos cargos conocidos de Samuel Wadsworth.
| Empresas | Cargo | Fin |
|---|---|---|
| DIMENSION THERAPEUTICS INC | Director Técnico/Científico/I+D | 01/11/2017 |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01/01/2013 |
Sanofi-Aventis U.S. LLC
 Sanofi-Aventis U.S. LLC Pharmaceuticals: MajorHealth Technology Sanofi-Aventis U.S. LLC engages in the provision of pharmaceutical products. It discovers, develops, produces and markets innovative therapies. The firm extensive research and development efforts are focused on health care challenges in cardiology, oncology and internal medicine, as well as metabolic diseases, central nervous system disorders, ophthalmology and vaccines. The company is headquartered in Bridgewater, NJ. | Corporate Officer/Principal | - |
Formación de Samuel Wadsworth.
| The University of Chicago | Doctorate Degree |
| Southern Illinois University | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| ULTRAGENYX PHARMACEUTICAL INC. | Health Technology |
| PRECISION BIOSCIENCES, INC. | Health Technology |
| Empresas privadas | 3 |
|---|---|
Dimension Therapeutics, Inc.
 Dimension Therapeutics, Inc. BiotechnologyHealth Technology Dimension Therapeutics, Inc. engages in the development of novel treatments for rare diseases. Its activities include discoveries and development of therapeutic products for people living with rare diseases associated wit the liver and caused by genetic mutations. The company was founded by Ben Auspitz in June 20, 2013 and is headquartered in Cambridge, MA. | Health Technology |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Sanofi-Aventis U.S. LLC
Sanofi-Aventis U.S. LLC Pharmaceuticals: MajorHealth Technology Sanofi-Aventis U.S. LLC engages in the provision of pharmaceutical products. It discovers, develops, produces and markets innovative therapies. The firm extensive research and development efforts are focused on health care challenges in cardiology, oncology and internal medicine, as well as metabolic diseases, central nervous system disorders, ophthalmology and vaccines. The company is headquartered in Bridgewater, NJ. | Health Technology |
- Bolsa de valores
- Insiders
- Samuel Wadsworth
